Freyja Healthcare, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for VereSee™, the company's second-generation Mini Laparoscope with VisualEntry™ System. This clearance marks a significant step forward in the company's mission to enhance visualization at the earliest stages of minimally invasive surgery.
VereSee is designed to bring direct visualization to laparoscopic entry, combining a miniature 2mm laparoscope with the VisualEntry™ System. By enabling surgeons to see anatomy during the entry process, VereSee introduces a novel approach to one of the most critical steps in laparoscopic procedures. The device is cleared as a Class II Endoscope and Accessories device under the 510(k) pathway.
“FDA clearance of VereSee is an incredibly important milestone for Freyja Healthcare,” said Mike MacKinnon, CEO of Freyja Healthcare. “We believe surgeons should have the ability to see when it matters most. VereSee brings visualization to the very beginning of the procedure while also providing the functionality of a miniature laparoscope, which may enable surgeons to avoid opening an additional laparoscope for certain procedures.”
Traditional laparoscopic entry often occurs without direct visualization, relying on blind techniques such as Veress needle insertion or trocar placement. VereSee aims to change this by providing real-time imaging during entry, potentially reducing the risk of complications and improving procedural outcomes. Once access is achieved, surgeons have the option to continue using the same miniature scope for visualization, potentially eliminating the need for a separate laparoscope.
The system pairs single-use entry components with reusable visualization technology, creating a platform that integrates into existing surgical workflows while supporting a practical healthcare economic model. This design may offer cost efficiencies and reduce waste, aligning with the growing emphasis on value-based care.
“VereSee represents more than a new method of laparoscopic entry,” said Jon I. Einarsson, MD, founder of Freyja Healthcare. “It is a miniature laparoscopic visualization platform that gives surgeons the opportunity to see anatomy from the moment of entry. We believe that has the potential to fundamentally change how surgeons think about access, while continuing to advance the miniaturization of laparoscopic visualization and scope functionality.”
The FDA clearance is a pivotal achievement for Freyja Healthcare, a company focused on developing innovative solutions for minimally invasive surgery and women's health. The technology is designed to address unmet needs for physicians, healthcare systems, and patients by improving visualization, access, and procedural efficiency.
With this clearance, Freyja Healthcare will begin the commercial introduction of VereSee and expand access to the technology among hospitals, ambulatory surgical centers, and surgeons performing minimally invasive procedures. The company aims to bring this advancement to a broader audience, potentially setting a new standard for laparoscopic entry.
The implications of this clearance are significant. By enabling visualization during entry, VereSee could reduce the risk of vascular or bowel injury, which are rare but serious complications of laparoscopic surgery. Furthermore, the miniature size and dual functionality may enhance surgical precision and reduce the number of incisions needed, leading to faster recovery times and improved patient satisfaction.
In an era where patient safety and cost-effectiveness are paramount, VereSee offers a promising solution that aligns with the shift toward minimally invasive techniques. As Freyja Healthcare prepares for commercial launch, the medical community will be watching closely to see how this technology is adopted and whether it becomes a standard tool in laparoscopic procedures.
